Who are Vidarabin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Suganon, Nesina, Suiny, Tradjenta, Tradjenta, Jalra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vidarabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vidarabin — Competitive Intelligence Brief

Vidarabin (VIDARABINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vidarabine. Area: Infectious Disease.

marketed vidarabine Dipeptidyl peptidase 4 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vidarabin (VIDARABINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vidarabin TARGET	VIDARABINE		marketed	vidarabine	Dipeptidyl peptidase 4	1976-01-01
Suganon	EVOGLIPTIN	Dong-A ST	marketed		Dipeptidyl peptidase 4	2015-01-01
Nesina	ALOGLIPTIN	Takeda	marketed	Dipeptidyl Peptidase 4 Inhibitor	Dipeptidyl peptidase 4	2013-01-01
Suiny	ANAGLIPTIN		marketed		Dipeptidyl peptidase 4	2012-01-01
Tradjenta	LINAGLIPTIN	Boehringer Ingelheim	marketed	Dipeptidyl Peptidase 4 Inhibitor [EPC]	Dipeptidyl peptidase 4	2011-01-01
Tradjenta	BI 1356	Boehringer Ingelheim	marketed	Dipeptidyl Peptidase 4 Inhibitor [EPC]	Dipeptidyl peptidase 4	2011-01-01
Jalra	VILDAGLIPTIN		marketed	vildagliptin	Dipeptidyl peptidase 4	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-26 — Tradjenta · 8883805*PED · US
2027-04-15 — Tradjenta · 7713938 · US
2027-05-04 — Tradjenta · 8673927 · US
2027-05-04 — Tradjenta · 9173859 · US
2027-05-04 — Tradjenta · 11033552 · US
2027-10-15 — Tradjenta · 7713938*PED · US
2027-11-04 — Tradjenta · 11033552*PED · US
2027-11-04 — Tradjenta · 9173859*PED · US
2027-11-04 — Tradjenta · 8673927*PED · US
2028-08-01 — Tradjenta · 7579449 · US
2029-02-01 — Tradjenta · 7579449*PED · US
2029-04-02 — Tradjenta · 9415016 · US
2029-04-02 — Tradjenta · 10973827 · US
2029-04-02 — Tradjenta · 10022379 · US
2029-08-05 — Tradjenta · 9486526 · US
2029-08-05 — Tradjenta · 10034877 · US
2029-10-02 — Tradjenta · 9415016*PED · US
2029-10-02 — Tradjenta · 10022379*PED · US
2029-10-02 — Tradjenta · 10973827*PED · US
2029-10-14 — Tradjenta · 8551957 · US
2030-02-05 — Tradjenta · 9486526*PED · US
2030-02-05 — Tradjenta · 10034877*PED · US
2030-04-14 — Tradjenta · 8551957*PED · US
2030-05-21 — Tradjenta · 9155705 · US
2030-06-04 — Tradjenta · 8846695 · US
2030-06-15 — Tradjenta · 10406172 · US
2030-11-21 — Tradjenta · 9155705*PED · US
2030-12-04 — Tradjenta · 8846695*PED · US
2031-03-05 — Tradjenta · 8853156 · US
2031-09-05 — Tradjenta · 8853156*PED · US

Sponsor landscape (vidarabine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vidarabin — Competitive Intelligence Brief. https://druglandscape.com/ci/vidarabine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab